moon-To The Moon - Tiger Brokers Online Investing Community

1
Comment
Favorite

jazlynnsee
2021-02-06

moon

The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 25)

The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

Top
Latest

No comments yet

Most Discussed

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":380577109,"tweetId":"380577109","gmtCreate":1612569417501,"gmtModify":1704872934454,"author":{"id":3572496339521414,"idStr":"3572496339521414","authorId":3572496339521414,"authorIdStr":"3572496339521414","name":"jazlynnsee","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>moon</body></html>","htmlText":"<html><head></head><body>moon</body></html>","text":"moon","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/380577109","repostId":2106729114,"repostType":2,"repost":{"id":"2106729114","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1611670059,"share":"https://ttm.financial/m/news/2106729114?lang=en_US&edition=fundamental","pubTime":"2021-01-26 22:07","market":"us","language":"en","title":"The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2106729114","media":"Benzinga","summary":"Here&#39;s a roundup of top developments in the biotech space over the last 24 hours:\n\nScaling The Peaks\n\n(Biotech Stocks Hitting 52-week Highs Jan. 25)","content":"<html><body>Here's a roundup of top developments in the biotech space over the last 24 hours:\n<h3>Scaling The Peaks</h3>\n(Biotech Stocks Hitting 52-week Highs Jan. 25)\n<ul>\n<li>Abbott Laboratories (NYSE:ABT)</li>\n<li>Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)</li>\n<li>Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)</li>\n<li>Antares Pharma Inc (NASDAQ:ATRS)</li>\n<li><a href=\"https://laohu8.com/S/AMTI\">Applied Molecular Transport Inc.</a> (NASDAQ:AMTI)</li>\n<li>argenx SE – ADR (NASDAQ:ARGX)</li>\n<li><a href=\"https://laohu8.com/S/AUPH\">Aurinia Pharmaceuticals Inc</a> (NASDAQ:AUPH) (announced FDA approval for its oral lupus nephritis drug)</li>\n<li>Axonics Modulation Technologies Inc (NASDAQ:AXNX)</li>\n<li>Beigene Ltd (NASDAQ:BGNE)</li>\n<li>BioNano Genomics Inc (NASDAQ:BNGO) (reacted to positive sell-side commentary)</li>\n<li><a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a> (NASDAQ:SAVA)</li>\n<li><a href=\"https://laohu8.com/S/CCXI\">ChemoCentryx</a> Inc (NASDAQ:CCXI)</li>\n<li>Clearpoint Neuro Inc (NASDAQ:CLPT)</li>\n<li>DarioHealth Corp (NASDAQ:DRIO)</li>\n<li>DermTech Inc (NASDAQ:DMTK)</li>\n<li><a href=\"https://laohu8.com/S/EDAP\">Edap Tms SA</a>(NASDAQ:EDAP)</li>\n<li>Eli Lilly And Co (NYSE:LLY) (reacted to positive Phase 3 data for its COVID-19 antibody treatment bamlanivimab)</li>\n<li><a href=\"https://laohu8.com/S/EKSO\">Ekso Bionics Holdings Inc</a> (NASDAQ:EKSO)</li>\n<li><a href=\"https://laohu8.com/S/NDRA\">ENDRA Life Sciences Inc</a> (NASDAQ:NDRA)</li>\n<li>Evogene Ltd (NASDAQ:EVGN)</li>\n<li>EXACT Sciences Corporation (NASDAQ:EXAS)</li>\n<li>GW Pharmaceuticals <a href=\"https://laohu8.com/S/PLC\">PLC</a>- ADR (NASDAQ:GWPH)</li>\n<li>Halozyme Therapeutics, Inc. (NASDAQ:HALO)</li>\n<li>Harvard Bioscience, Inc. (NASDAQ:HBIO)</li>\n<li><a href=\"https://laohu8.com/S/ILMN\">Illumina</a>, Inc. (NASDAQ:ILMN)</li>\n<li>Inari Medical Inc (NASDAQ:NARI)</li>\n<li><a href=\"https://laohu8.com/S/INSM\">Insmed</a> Incorporated (NASDAQ:INSM)</li>\n<li>Ionis Pharmaceuticals Inc (NASDAQ:IONS)</li>\n<li>Jazz Pharmaceuticals PLC (NASDAQ: JAZZ</li>\n<li>Jounce Therapeutics Inc(NASDAQ:JNCE)</li>\n<li>Kintara Therapeutics Inc (NASDAQ:KTRA)</li>\n<li>Krystal Biotech Inc(NASDAQ:KRYS)</li>\n<li>LeMaitre Vascular Inc (NASDAQ:LMAT)</li>\n<li><a href=\"https://laohu8.com/S/LGND\">Ligand Pharmaceuticals Inc.</a> (NASDAQ:LGND)</li>\n<li><a href=\"https://laohu8.com/S/MMSI\">Merit Medical Systems</a>, Inc. (NASDAQ:MMSI)</li>\n<li>Mustang Bio Inc (NASDAQ:MBIO)</li>\n<li><a href=\"https://laohu8.com/S/OMCL\">Omnicell</a>, Inc. (NASDAQ:OMCL)</li>\n<li>Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP)</li>\n<li><a href=\"https://laohu8.com/S/PEN\">Penumbra Inc</a> (NYSE:PEN)</li>\n<li>Profound Medical Corp(NASDAQ:PROF)</li>\n<li>Pulse Biosciences Inc (NASDAQ:PLSE) (announced CE mark approval for the CellFX System for the treatment of general dermatologic conditions)</li>\n<li>Renalytix AI PLC (NASDAQ:RNLX)</li>\n<li>Rhythm Pharmaceuticals Inc (NASDAQ:RYTM)</li>\n<li>Seelos Therapeutics Inc (NASDAQ:SEEL)</li>\n<li>SI-Bone Inc (NASDAQ:SIBN)</li>\n<li>Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ:SLN)</li>\n<li>SpringWorks Therapeutics Inc (NASDAQ:SWTX)</li>\n<li><a href=\"https://laohu8.com/S/SUPN\">Supernus Pharmaceuticals</a> Inc (NASDAQ:SUPN)</li>\n<li><a href=\"https://laohu8.com/S/TMDI\">Titan Medical Inc.</a> (NASDAQ:TMDI)</li>\n<li>Vericel Corp (NASDAQ:VCEL)</li>\n<li>Vistagen Therapeutics Inc (NASDAQ:VTGN)</li>\n</ul>\n<h3>Down In The Dumps</h3>\nNone of the biotech/medical device/diagnostic stocks hit 52-week highs in the session.\n<h3>Stocks In Focus</h3>\n<h3>Novartis Q4 Results Trail Expectations</h3>\nNovartis AG (NYSE:NVS) reported a 3% year-over-year increase in fourth-quarter sales to $12.77 billion. The core EPS increased from $1.32 to $1.34. Analysts, on average, estimated EPS of $1.36 on revenue of $12.87 billion.\nFor 2021, the company expects constant currency sales growth in the low-to-mid single digit range and core operating income to rise in the mid-single digit range.\nThe stock was down 3.77% to $94.76 premarket Tuesday.\n<h3>Amarin Includes HealthNet In Patent Infringement Lawsuit</h3>\nAmarin Corporation plc (NASDAQ:AMRN) said it has expanded the scope of its Vascepa patent infringement lawsuit against Hikma Pharma to include Health Net, a health care insurance provider in the U.S.\nAmarin alleged that Health Net has actively induced pharmacies to dispense, and patients to use, Hikma generic icosapent ethyl capsules in infringement of three U.S. patents related to Vascepa.\nA vast majority of Vascepa prescriptions are for use in cardiovascular risk reduction, and Hikma does not have an FDA-approved indication for that use, and inducement for such use would infringe the subject patents, Amarin said.\nAmarin shares were rising 2.12% to $7.72 premarket Tuesday. \n<h3>Spectrum Pharma Rises On Fund Stake Disclosure</h3>\n<a href=\"https://laohu8.com/S/SPPI\">Spectrum Pharmaceuticals</a>, Inc. (NASDAQ:SPPI) shares rallied after BlackRock, Inc. (NYSE:BLK) revealed in a filing it beneficially owns an aggregate of 27.82 million shares in the company, giving it a 19.1% stake.\nThe stock was up 2.55% to $4.02 premarket. \nRelated Link: The Week Ahead In Biotech (Jan 24-30): J&amp;J, Lilly to Kickstart Big Pharma Earnings, Amgen FDA Decision and More \n<h3>Lilly's Antibody Combo Treatment Aces Late-Stage Study In High-Risk COVID-19 Patients</h3>\nLilly said its bamlanivimab, 2,800 mg, and etesevimab, 2,800 mg, together significantly reduced COVID-19-related hospitalizations and deaths in high-risk patients recently diagnosed with COVID-19, meeting the primary endpoint of the Phase 3 BLAZE-1 trial.\n\"Notably, the 70 percent decrease in risk of hospitalizations or death seen in this Phase 3 trial of bamlanivimab and etesevimab together is consistent with the reduction in risk of hospitalization or ER visits seen with bamlanivimab alone in the Phase 2 trial,\" Lilly said.\nIn premarket trading Tuesday, the shares were advancing 1.18% to $214.85. \n<h3>Morphosys Set For $1.5M Milestone Payment From I-Mab As Phase 1 Study Of Monoclonal Antibody In Solid Tumors Commences</h3>\nI-Mab ADR (NASDAQ:IMAB) and Morphosys Ag (NASDAQ:MOR) announced the commencement of a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of MOR210/TJ210 monotherapy in patients with relapsed or refractory advanced solid tumors in the U.S., with the first patient being dosed.\nMOR210/TJ210 is a monoclonal antibody developed by MorphoSys that is directed against complement factor C5a receptor 1.\nMorphoSys will receive a $1.5-million payment from I-Mab for achieving this milestone under the license agreement between the two companies. The licensing deal between the companies announced in November 2018 provides I-Mab exclusive rights to develop and commercialize MOR210/TJ210 in Greater China and South Korea, while MorphoSys retains rights in other parts of the world.\nIn premarket trading Tuesday, I-Mab shares were moving up 2.78% to $54.44.\n<h3>Axonics Q4, FY20 Revenue Guidance Below Consensus Estimates</h3>\nAxonics Modulation preannounced fourth-quarter revenue in the range of $34.7 million to $34.9 million, sharply higher than the $9.9 million in the year-ago quarter. For the full-year, the company expects revenue of about $111.5 million compared to the year-ago revenue of $13.8 million.\nThe guidance range trailed the consensus estimates that call for revenue of $35.48 million for the quarter and $112.31 million for the year.\n<h3>Merck's Keytruda Gets Label Expansion In Europe</h3>\nMerck &amp; Co., Inc. (NYSE:MRK) said the European Commission has approved its Keytruda as a monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.\nThe stock was down 0.18% to $81 in premarket trading Tuesday.\n<h3>Offerings</h3>\nGerman coronavirus vaccine developer CureVac BV (NASDAQ:CVAC) announced an underwritten public offering of 5 million common shares.\nThe stock was down 2.6% to $101.78 premarket Tuesday. \nSeelos said it has commenced a proposed underwritten public offering of shares of common stock. All of the shares of common stock in the offering will be sold by the company.\nThe stock was tumbling 9.02% to $2.42 premarket Tuesday.\n<a href=\"https://laohu8.com/S/LPCN\">Lipocine Inc</a> (NASDAQ:LPCN) said it intends to offer shares of its common stock in an underwritten public offering. All of the shares in the proposed offering are to be sold by Lipocine.\nIn premarket trading Tuesday, the stock was retreating 11.36% to $1.95. \n<h3>On The Radar</h3>\nClinical Readouts\nRhythm Pharma is hosting a virtual event from 8-10 a.m. Tuesday to provide an update on its ongoing exploratory Phase 2 Basket Study and genetic sequencing efforts.\nThe company will present data for setmelanotide in individuals living with heterozygous obesity due to genetic variants in <a href=\"https://laohu8.com/S/AONE\">one</a> of two alleles of the POMC, PCSK1 or LEPR gene, as well as SRC1 and SH2B1 deficiency obesities.\nIt will also provide an update on data from its sequencing efforts, which now comprise samples from approximately 37,500 individuals with severe obesity.\n<h3>Earnings</h3>\nJohnson &amp; Johnson (NYSE:JNJ) (Q4 revenue of $22.48 billion vs. $21.67-billion estimate, adjusted EPS $1.86 vs. $1.82 consensus, FY21 adjusted EPS guidance above consensus)\nVarian Medical Systems, Inc. (NYSE:VAR) (after the close)\nRelated Link: Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates \n</body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\nBenzinga \n2021-01-26 22:07\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body>Here's a roundup of top developments in the biotech space over the last 24 hours:\n<h3>Scaling The Peaks</h3>\n(Biotech Stocks Hitting 52-week Highs Jan. 25)\n<ul>\n<li>Abbott Laboratories (NYSE:ABT)</li>\n<li>Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)</li>\n<li>Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)</li>\n<li>Antares Pharma Inc (NASDAQ:ATRS)</li>\n<li><a href=\"https://laohu8.com/S/AMTI\">Applied Molecular Transport Inc.</a> (NASDAQ:AMTI)</li>\n<li>argenx SE – ADR (NASDAQ:ARGX)</li>\n<li><a href=\"https://laohu8.com/S/AUPH\">Aurinia Pharmaceuticals Inc</a> (NASDAQ:AUPH) (announced FDA approval for its oral lupus nephritis drug)</li>\n<li>Axonics Modulation Technologies Inc (NASDAQ:AXNX)</li>\n<li>Beigene Ltd (NASDAQ:BGNE)</li>\n<li>BioNano Genomics Inc (NASDAQ:BNGO) (reacted to positive sell-side commentary)</li>\n<li><a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a> (NASDAQ:SAVA)</li>\n<li><a href=\"https://laohu8.com/S/CCXI\">ChemoCentryx</a> Inc (NASDAQ:CCXI)</li>\n<li>Clearpoint Neuro Inc (NASDAQ:CLPT)</li>\n<li>DarioHealth Corp (NASDAQ:DRIO)</li>\n<li>DermTech Inc (NASDAQ:DMTK)</li>\n<li><a href=\"https://laohu8.com/S/EDAP\">Edap Tms SA</a>(NASDAQ:EDAP)</li>\n<li>Eli Lilly And Co (NYSE:LLY) (reacted to positive Phase 3 data for its COVID-19 antibody treatment bamlanivimab)</li>\n<li><a href=\"https://laohu8.com/S/EKSO\">Ekso Bionics Holdings Inc</a> (NASDAQ:EKSO)</li>\n<li><a href=\"https://laohu8.com/S/NDRA\">ENDRA Life Sciences Inc</a> (NASDAQ:NDRA)</li>\n<li>Evogene Ltd (NASDAQ:EVGN)</li>\n<li>EXACT Sciences Corporation (NASDAQ:EXAS)</li>\n<li>GW Pharmaceuticals <a href=\"https://laohu8.com/S/PLC\">PLC</a>- ADR (NASDAQ:GWPH)</li>\n<li>Halozyme Therapeutics, Inc. (NASDAQ:HALO)</li>\n<li>Harvard Bioscience, Inc. (NASDAQ:HBIO)</li>\n<li><a href=\"https://laohu8.com/S/ILMN\">Illumina</a>, Inc. (NASDAQ:ILMN)</li>\n<li>Inari Medical Inc (NASDAQ:NARI)</li>\n<li><a href=\"https://laohu8.com/S/INSM\">Insmed</a> Incorporated (NASDAQ:INSM)</li>\n<li>Ionis Pharmaceuticals Inc (NASDAQ:IONS)</li>\n<li>Jazz Pharmaceuticals PLC (NASDAQ: JAZZ</li>\n<li>Jounce Therapeutics Inc(NASDAQ:JNCE)</li>\n<li>Kintara Therapeutics Inc (NASDAQ:KTRA)</li>\n<li>Krystal Biotech Inc(NASDAQ:KRYS)</li>\n<li>LeMaitre Vascular Inc (NASDAQ:LMAT)</li>\n<li><a href=\"https://laohu8.com/S/LGND\">Ligand Pharmaceuticals Inc.</a> (NASDAQ:LGND)</li>\n<li><a href=\"https://laohu8.com/S/MMSI\">Merit Medical Systems</a>, Inc. (NASDAQ:MMSI)</li>\n<li>Mustang Bio Inc (NASDAQ:MBIO)</li>\n<li><a href=\"https://laohu8.com/S/OMCL\">Omnicell</a>, Inc. (NASDAQ:OMCL)</li>\n<li>Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP)</li>\n<li><a href=\"https://laohu8.com/S/PEN\">Penumbra Inc</a> (NYSE:PEN)</li>\n<li>Profound Medical Corp(NASDAQ:PROF)</li>\n<li>Pulse Biosciences Inc (NASDAQ:PLSE) (announced CE mark approval for the CellFX System for the treatment of general dermatologic conditions)</li>\n<li>Renalytix AI PLC (NASDAQ:RNLX)</li>\n<li>Rhythm Pharmaceuticals Inc (NASDAQ:RYTM)</li>\n<li>Seelos Therapeutics Inc (NASDAQ:SEEL)</li>\n<li>SI-Bone Inc (NASDAQ:SIBN)</li>\n<li>Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ:SLN)</li>\n<li>SpringWorks Therapeutics Inc (NASDAQ:SWTX)</li>\n<li><a href=\"https://laohu8.com/S/SUPN\">Supernus Pharmaceuticals</a> Inc (NASDAQ:SUPN)</li>\n<li><a href=\"https://laohu8.com/S/TMDI\">Titan Medical Inc.</a> (NASDAQ:TMDI)</li>\n<li>Vericel Corp (NASDAQ:VCEL)</li>\n<li>Vistagen Therapeutics Inc (NASDAQ:VTGN)</li>\n</ul>\n<h3>Down In The Dumps</h3>\nNone of the biotech/medical device/diagnostic stocks hit 52-week highs in the session.\n<h3>Stocks In Focus</h3>\n<h3>Novartis Q4 Results Trail Expectations</h3>\nNovartis AG (NYSE:NVS) reported a 3% year-over-year increase in fourth-quarter sales to $12.77 billion. The core EPS increased from $1.32 to $1.34. Analysts, on average, estimated EPS of $1.36 on revenue of $12.87 billion.\nFor 2021, the company expects constant currency sales growth in the low-to-mid single digit range and core operating income to rise in the mid-single digit range.\nThe stock was down 3.77% to $94.76 premarket Tuesday.\n<h3>Amarin Includes HealthNet In Patent Infringement Lawsuit</h3>\nAmarin Corporation plc (NASDAQ:AMRN) said it has expanded the scope of its Vascepa patent infringement lawsuit against Hikma Pharma to include Health Net, a health care insurance provider in the U.S.\nAmarin alleged that Health Net has actively induced pharmacies to dispense, and patients to use, Hikma generic icosapent ethyl capsules in infringement of three U.S. patents related to Vascepa.\nA vast majority of Vascepa prescriptions are for use in cardiovascular risk reduction, and Hikma does not have an FDA-approved indication for that use, and inducement for such use would infringe the subject patents, Amarin said.\nAmarin shares were rising 2.12% to $7.72 premarket Tuesday. \n<h3>Spectrum Pharma Rises On Fund Stake Disclosure</h3>\n<a href=\"https://laohu8.com/S/SPPI\">Spectrum Pharmaceuticals</a>, Inc. (NASDAQ:SPPI) shares rallied after BlackRock, Inc. (NYSE:BLK) revealed in a filing it beneficially owns an aggregate of 27.82 million shares in the company, giving it a 19.1% stake.\nThe stock was up 2.55% to $4.02 premarket. \nRelated Link: The Week Ahead In Biotech (Jan 24-30): J&amp;J, Lilly to Kickstart Big Pharma Earnings, Amgen FDA Decision and More \n<h3>Lilly's Antibody Combo Treatment Aces Late-Stage Study In High-Risk COVID-19 Patients</h3>\nLilly said its bamlanivimab, 2,800 mg, and etesevimab, 2,800 mg, together significantly reduced COVID-19-related hospitalizations and deaths in high-risk patients recently diagnosed with COVID-19, meeting the primary endpoint of the Phase 3 BLAZE-1 trial.\n\"Notably, the 70 percent decrease in risk of hospitalizations or death seen in this Phase 3 trial of bamlanivimab and etesevimab together is consistent with the reduction in risk of hospitalization or ER visits seen with bamlanivimab alone in the Phase 2 trial,\" Lilly said.\nIn premarket trading Tuesday, the shares were advancing 1.18% to $214.85. \n<h3>Morphosys Set For $1.5M Milestone Payment From I-Mab As Phase 1 Study Of Monoclonal Antibody In Solid Tumors Commences</h3>\nI-Mab ADR (NASDAQ:IMAB) and Morphosys Ag (NASDAQ:MOR) announced the commencement of a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of MOR210/TJ210 monotherapy in patients with relapsed or refractory advanced solid tumors in the U.S., with the first patient being dosed.\nMOR210/TJ210 is a monoclonal antibody developed by MorphoSys that is directed against complement factor C5a receptor 1.\nMorphoSys will receive a $1.5-million payment from I-Mab for achieving this milestone under the license agreement between the two companies. The licensing deal between the companies announced in November 2018 provides I-Mab exclusive rights to develop and commercialize MOR210/TJ210 in Greater China and South Korea, while MorphoSys retains rights in other parts of the world.\nIn premarket trading Tuesday, I-Mab shares were moving up 2.78% to $54.44.\n<h3>Axonics Q4, FY20 Revenue Guidance Below Consensus Estimates</h3>\nAxonics Modulation preannounced fourth-quarter revenue in the range of $34.7 million to $34.9 million, sharply higher than the $9.9 million in the year-ago quarter. For the full-year, the company expects revenue of about $111.5 million compared to the year-ago revenue of $13.8 million.\nThe guidance range trailed the consensus estimates that call for revenue of $35.48 million for the quarter and $112.31 million for the year.\n<h3>Merck's Keytruda Gets Label Expansion In Europe</h3>\nMerck &amp; Co., Inc. (NYSE:MRK) said the European Commission has approved its Keytruda as a monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.\nThe stock was down 0.18% to $81 in premarket trading Tuesday.\n<h3>Offerings</h3>\nGerman coronavirus vaccine developer CureVac BV (NASDAQ:CVAC) announced an underwritten public offering of 5 million common shares.\nThe stock was down 2.6% to $101.78 premarket Tuesday. \nSeelos said it has commenced a proposed underwritten public offering of shares of common stock. All of the shares of common stock in the offering will be sold by the company.\nThe stock was tumbling 9.02% to $2.42 premarket Tuesday.\n<a href=\"https://laohu8.com/S/LPCN\">Lipocine Inc</a> (NASDAQ:LPCN) said it intends to offer shares of its common stock in an underwritten public offering. All of the shares in the proposed offering are to be sold by Lipocine.\nIn premarket trading Tuesday, the stock was retreating 11.36% to $1.95. \n<h3>On The Radar</h3>\nClinical Readouts\nRhythm Pharma is hosting a virtual event from 8-10 a.m. Tuesday to provide an update on its ongoing exploratory Phase 2 Basket Study and genetic sequencing efforts.\nThe company will present data for setmelanotide in individuals living with heterozygous obesity due to genetic variants in <a href=\"https://laohu8.com/S/AONE\">one</a> of two alleles of the POMC, PCSK1 or LEPR gene, as well as SRC1 and SH2B1 deficiency obesities.\nIt will also provide an update on data from its sequencing efforts, which now comprise samples from approximately 37,500 individuals with severe obesity.\n<h3>Earnings</h3>\nJohnson &amp; Johnson (NYSE:JNJ) (Q4 revenue of $22.48 billion vs. $21.67-billion estimate, adjusted EPS $1.86 vs. $1.82 consensus, FY21 adjusted EPS guidance above consensus)\nVarian Medical Systems, Inc. (NYSE:VAR) (after the close)\nRelated Link: Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates \n</body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GWPH":"GW Pharmaceuticals plc","MRK":"默沙东","LMAT":"勒梅特微管医疗","CLPT":"ClearPoint Neuro, Inc.","VCEL":"Vericel Corporation","CCXI":"ChemoCentryx","MMSI":"Merit Medical Systems","IONS":"Ionis Pharmaceuticals, Inc","AMRN":"阿玛琳","RYTM":"Rhythm Pharmaceuticals Inc.","LPCN":"Lipocine Inc","KRYS":"Krystal Biotech Inc.","LGND":"Ligand Pharmaceuticals Inc.","DRIO":"DarioHealth","EXAS":"精密科学","SEEL":"Seelos Therapeutics, Inc.","ALNY":"阿尔尼拉姆制药公司","NDRA":"ENDRA Life Sciences Inc","VTGN":"VistaGen Therapeutics, Inc.","OMCL":"Omnicell","SWTX":"SpringWorks Therapeutics, Inc.","SPPI":"Spectrum Pharmaceuticals","INSM":"Insmed","ARGX":"Argenx SE","ILMN":"Illumina","CVAC":"CureVac B.V.","MOR":"Morphosys AG","JNJ":"强生","ORMP":"Oramed Pharmaceuticals Inc.","EDAP":"Edap Tms SA","LLY":"礼来","ALXN":"亚力兄制药","SLN":"Silence Therapeutics Plc","SAVA":"Cassava Sciences Inc","AMTI":"Applied Molecular Transport Inc.","NARI":"Inari Medical, Inc.","AXNX":"Axonics Inc.","SUPN":"Supernus Pharmaceuticals","MBIO":"Mustang Bio, Inc","PROF":"Profound Medical Corp.","SIBN":"SI-BONE, Inc.","HALO":"奥洛兹美医疗","PEN":"Penumbra Inc"},"source_url":"https://www.benzinga.com/node/19317089","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2106729114","content_text":"Here's a roundup of top developments in the biotech space over the last 24 hours:\nScaling The Peaks\n(Biotech Stocks Hitting 52-week Highs Jan. 25)\n\nAbbott Laboratories (NYSE:ABT)\nAlexion Pharmaceuticals, Inc. (NASDAQ:ALXN)\nAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)\nAntares Pharma Inc (NASDAQ:ATRS)\nApplied Molecular Transport Inc. (NASDAQ:AMTI)\nargenx SE – ADR (NASDAQ:ARGX)\nAurinia Pharmaceuticals Inc (NASDAQ:AUPH) (announced FDA approval for its oral lupus nephritis drug)\nAxonics Modulation Technologies Inc (NASDAQ:AXNX)\nBeigene Ltd (NASDAQ:BGNE)\nBioNano Genomics Inc (NASDAQ:BNGO) (reacted to positive sell-side commentary)\nCassava Sciences Inc (NASDAQ:SAVA)\nChemoCentryx Inc (NASDAQ:CCXI)\nClearpoint Neuro Inc (NASDAQ:CLPT)\nDarioHealth Corp (NASDAQ:DRIO)\nDermTech Inc (NASDAQ:DMTK)\nEdap Tms SA(NASDAQ:EDAP)\nEli Lilly And Co (NYSE:LLY) (reacted to positive Phase 3 data for its COVID-19 antibody treatment bamlanivimab)\nEkso Bionics Holdings Inc (NASDAQ:EKSO)\nENDRA Life Sciences Inc (NASDAQ:NDRA)\nEvogene Ltd (NASDAQ:EVGN)\nEXACT Sciences Corporation (NASDAQ:EXAS)\nGW Pharmaceuticals PLC- ADR (NASDAQ:GWPH)\nHalozyme Therapeutics, Inc. (NASDAQ:HALO)\nHarvard Bioscience, Inc. (NASDAQ:HBIO)\nIllumina, Inc. (NASDAQ:ILMN)\nInari Medical Inc (NASDAQ:NARI)\nInsmed Incorporated (NASDAQ:INSM)\nIonis Pharmaceuticals Inc (NASDAQ:IONS)\nJazz Pharmaceuticals PLC (NASDAQ: JAZZ\nJounce Therapeutics Inc(NASDAQ:JNCE)\nKintara Therapeutics Inc (NASDAQ:KTRA)\nKrystal Biotech Inc(NASDAQ:KRYS)\nLeMaitre Vascular Inc (NASDAQ:LMAT)\nLigand Pharmaceuticals Inc. (NASDAQ:LGND)\nMerit Medical Systems, Inc. (NASDAQ:MMSI)\nMustang Bio Inc (NASDAQ:MBIO)\nOmnicell, Inc. (NASDAQ:OMCL)\nOramed Pharmaceuticals, Inc. (NASDAQ:ORMP)\nPenumbra Inc (NYSE:PEN)\nProfound Medical Corp(NASDAQ:PROF)\nPulse Biosciences Inc (NASDAQ:PLSE) (announced CE mark approval for the CellFX System for the treatment of general dermatologic conditions)\nRenalytix AI PLC (NASDAQ:RNLX)\nRhythm Pharmaceuticals Inc (NASDAQ:RYTM)\nSeelos Therapeutics Inc (NASDAQ:SEEL)\nSI-Bone Inc (NASDAQ:SIBN)\nSilence Therapeutics ADR Representing 3 Ord Shs (NASDAQ:SLN)\nSpringWorks Therapeutics Inc (NASDAQ:SWTX)\nSupernus Pharmaceuticals Inc (NASDAQ:SUPN)\nTitan Medical Inc. (NASDAQ:TMDI)\nVericel Corp (NASDAQ:VCEL)\nVistagen Therapeutics Inc (NASDAQ:VTGN)\n\nDown In The Dumps\nNone of the biotech/medical device/diagnostic stocks hit 52-week highs in the session.\nStocks In Focus\nNovartis Q4 Results Trail Expectations\nNovartis AG (NYSE:NVS) reported a 3% year-over-year increase in fourth-quarter sales to $12.77 billion. The core EPS increased from $1.32 to $1.34. Analysts, on average, estimated EPS of $1.36 on revenue of $12.87 billion.\nFor 2021, the company expects constant currency sales growth in the low-to-mid single digit range and core operating income to rise in the mid-single digit range.\nThe stock was down 3.77% to $94.76 premarket Tuesday.\nAmarin Includes HealthNet In Patent Infringement Lawsuit\nAmarin Corporation plc (NASDAQ:AMRN) said it has expanded the scope of its Vascepa patent infringement lawsuit against Hikma Pharma to include Health Net, a health care insurance provider in the U.S.\nAmarin alleged that Health Net has actively induced pharmacies to dispense, and patients to use, Hikma generic icosapent ethyl capsules in infringement of three U.S. patents related to Vascepa.\nA vast majority of Vascepa prescriptions are for use in cardiovascular risk reduction, and Hikma does not have an FDA-approved indication for that use, and inducement for such use would infringe the subject patents, Amarin said.\nAmarin shares were rising 2.12% to $7.72 premarket Tuesday. \nSpectrum Pharma Rises On Fund Stake Disclosure\nSpectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) shares rallied after BlackRock, Inc. (NYSE:BLK) revealed in a filing it beneficially owns an aggregate of 27.82 million shares in the company, giving it a 19.1% stake.\nThe stock was up 2.55% to $4.02 premarket. \nRelated Link: The Week Ahead In Biotech (Jan 24-30): J&J, Lilly to Kickstart Big Pharma Earnings, Amgen FDA Decision and More \nLilly's Antibody Combo Treatment Aces Late-Stage Study In High-Risk COVID-19 Patients\nLilly said its bamlanivimab, 2,800 mg, and etesevimab, 2,800 mg, together significantly reduced COVID-19-related hospitalizations and deaths in high-risk patients recently diagnosed with COVID-19, meeting the primary endpoint of the Phase 3 BLAZE-1 trial.\n\"Notably, the 70 percent decrease in risk of hospitalizations or death seen in this Phase 3 trial of bamlanivimab and etesevimab together is consistent with the reduction in risk of hospitalization or ER visits seen with bamlanivimab alone in the Phase 2 trial,\" Lilly said.\nIn premarket trading Tuesday, the shares were advancing 1.18% to $214.85. \nMorphosys Set For $1.5M Milestone Payment From I-Mab As Phase 1 Study Of Monoclonal Antibody In Solid Tumors Commences\nI-Mab ADR (NASDAQ:IMAB) and Morphosys Ag (NASDAQ:MOR) announced the commencement of a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of MOR210/TJ210 monotherapy in patients with relapsed or refractory advanced solid tumors in the U.S., with the first patient being dosed.\nMOR210/TJ210 is a monoclonal antibody developed by MorphoSys that is directed against complement factor C5a receptor 1.\nMorphoSys will receive a $1.5-million payment from I-Mab for achieving this milestone under the license agreement between the two companies. The licensing deal between the companies announced in November 2018 provides I-Mab exclusive rights to develop and commercialize MOR210/TJ210 in Greater China and South Korea, while MorphoSys retains rights in other parts of the world.\nIn premarket trading Tuesday, I-Mab shares were moving up 2.78% to $54.44.\nAxonics Q4, FY20 Revenue Guidance Below Consensus Estimates\nAxonics Modulation preannounced fourth-quarter revenue in the range of $34.7 million to $34.9 million, sharply higher than the $9.9 million in the year-ago quarter. For the full-year, the company expects revenue of about $111.5 million compared to the year-ago revenue of $13.8 million.\nThe guidance range trailed the consensus estimates that call for revenue of $35.48 million for the quarter and $112.31 million for the year.\nMerck's Keytruda Gets Label Expansion In Europe\nMerck & Co., Inc. (NYSE:MRK) said the European Commission has approved its Keytruda as a monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.\nThe stock was down 0.18% to $81 in premarket trading Tuesday.\nOfferings\nGerman coronavirus vaccine developer CureVac BV (NASDAQ:CVAC) announced an underwritten public offering of 5 million common shares.\nThe stock was down 2.6% to $101.78 premarket Tuesday. \nSeelos said it has commenced a proposed underwritten public offering of shares of common stock. All of the shares of common stock in the offering will be sold by the company.\nThe stock was tumbling 9.02% to $2.42 premarket Tuesday.\nLipocine Inc (NASDAQ:LPCN) said it intends to offer shares of its common stock in an underwritten public offering. All of the shares in the proposed offering are to be sold by Lipocine.\nIn premarket trading Tuesday, the stock was retreating 11.36% to $1.95. \nOn The Radar\nClinical Readouts\nRhythm Pharma is hosting a virtual event from 8-10 a.m. Tuesday to provide an update on its ongoing exploratory Phase 2 Basket Study and genetic sequencing efforts.\nThe company will present data for setmelanotide in individuals living with heterozygous obesity due to genetic variants in one of two alleles of the POMC, PCSK1 or LEPR gene, as well as SRC1 and SH2B1 deficiency obesities.\nIt will also provide an update on data from its sequencing efforts, which now comprise samples from approximately 37,500 individuals with severe obesity.\nEarnings\nJohnson & Johnson (NYSE:JNJ) (Q4 revenue of $22.48 billion vs. $21.67-billion estimate, adjusted EPS $1.86 vs. $1.82 consensus, FY21 adjusted EPS guidance above consensus)\nVarian Medical Systems, Inc. (NYSE:VAR) (after the close)\nRelated Link: Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates","news_type":1,"symbols_score_info":{"ARGX":0.9,"AXNX":0.9,"DMTK":0.9,"SWTX":0.9,"GWPH":0.9,"KTRA":0.9,"EDAP":0.9,"RNLX":0.9,"JNJ":0.9,"DRIO":0.9,"ORMP":0.9,"SUPN":0.9,"ILMN":0.9,"MRK":0.9,"IONS":0.9,"AMRN":0.9,"ALXN":0.9,"PROF":0.9,"RYTM":0.9,"OMCL":0.9,"PEN":0.9,"LPCN":0.9,"ALNY":0.9,"JNCE":0.9,"KRYS":0.9,"SIBN":0.9,"EXAS":0.9,"VCEL":0.9,"SAVA":0.9,"CLPT":0.9,"VTGN":0.9,"AMTI":0.9,"CVAC":0.9,"NARI":0.9,"TMDI":0.9,"VAR":0.9,"IMAB":0.9,"LLY":0.9,"MMSI":0.9,"LGND":0.9,"LMAT":0.9,"MBIO":0.9,"HALO":0.9,"SLN":0.9,"CCXI":0.9,"SPPI":0.9,"INSM":0.9,"NDRA":0.9,"MOR":0.9,"SEEL":0.9}},"isVote":1,"tweetType":1,"viewCount":1170,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}